Investigating Endothelin 1 as a Marker for Kidney Issues in Sickle Cell Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the role of urinary endothelin 1 as a potential biomarker for renal impairment in patients with sickle cell disease (SCD) aged 1 to 18 years. By analyzing the levels of endothelin 1 in urine samples, researchers hope to identify correlations between these levels and kidney function in SCD patients. The study will include participants who meet specific inclusion criteria while excluding those with pre-existing renal diseases. The findings could enhance understanding of kidney complications in SCD and inform future management strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patients fulfilling all the following criteria will be included:
* Patients with sickle cell disease in the age range of 1-18years.

Exclusion Criteria:

* Patients diagnosed to have coexistent renal disease before the study

Where it's running

• Sohag university Hospital
  Sohag, Egypt Recruiting

Study contacts

• Study coordinator: Esraa A Quenawey, resident
• Email: esraaanwar@med.sohag.edu.eg
• Phone: 01026841188

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients

  This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07776444

• Adapting and testing PEN-Plus in Zambian primary care

  Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.

  Recruiting Centre for Infectious Disease Research in Zambia · Lusaka, Lusaka Province · NCT07753681

• Newborn Sickle Cell Screening in Mozambique

  We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.

  Recruiting St. Jude Children's Research Hospital · Nhamatanda, Sofala · NCT07719972

• Optimizing Hydroxyurea in Children with Sickle Cell in Africa

  This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.

  Recruiting Phase 1/2 Children's Hospital Medical Center, Cincinnati · Kampala · NCT07708714

• Hematopoietic stem cell editing to treat sickle cell disease

  This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.

  Recruiting Phase 1 Boston Children's Hospital · Boston, Massachusetts · NCT07708350

• Virtual reality options to help with VOC pain in adults with SCD

  This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.

  Recruiting University of Maryland, Baltimore · Baltimore, Maryland · NCT07674277

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.